We can readily understand why investors are attracted to unprofitable companies. Indeed, BriaCell Therapeutics...
Announced that the U.S. Food and Drug Administration has granted Fast Track status to BriaCell’s lead ...
U.S. Food and Drug Administration (FDA) has granted Fast Track status to BriaCell’s lead candidate, Bria-IMT™, for the treatment of metastatic breast cancer.Fast Track improves the speed and frequency of communication with FDA, potentially leading to earlier drug approval and access by patients.BriaCell is currently enrolling and dosing advanced breast cancer patients in a Phase I/IIa study, now with Fast Track designation. PHILADELPHIA and VANCOUVER, British Columbia, April 13, 2022 (GLOBE NEWS